NovaRx Corporation Completes Enrollment in Lucanix Pivitol Phase III Therapeutic Vaccine Trial for Post Frontline Maintenace Therapy in Non Small Cell Lung Cancer
6/20/2012 10:39:46 AM
More...
|
NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer
11/4/2009 7:57:04 AM
More...
|
NovaRx Corporation Appoints Industry Veteran as President and COO
12/4/2008 9:47:11 AM
More...
|
NovaRx Corporation Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8/21/2008 7:30:17 AM
More...
|
NovaRx Corporation Selects Image Solutions, Inc. (ISI)'s eCTDXPress and ISIWriter
5/1/2008 8:42:33 AM
More...
|
The Immune Response Corporation, Inc. (IMNR) Announces Receipt Of Milestone Payment From NovaRx Corporation
1/5/2007 11:50:51 AM
More...
|
NovaRx Corporation Release: Lucanix Phase II Clinical Data Demonstrates Significantly Increased Survival In Lung Cancer Patients
6/5/2006 10:22:27 AM
More...
|
NovaRx Corporation To Present Lucanix Phase II Clinical Data At American Society of Clinical Oncology
5/31/2006 10:19:59 AM
More...
|
NovaRx Corporation Achieves Full Enrollment Of Its Phase II Clinical Trial In Non-Small Cell Lung Cancer Ahead Of Schedule
10/19/2005 5:11:23 PM
More...
|
NovaRx Corporation Announces $2.2 Million Award Of SBIR Grant To Help Fund Its Pivotal Phase II/III Clinical Trial In Brain Cancer
10/19/2005 5:11:17 PM
More...
|
|